cigarettes), native born, lack of insurance coverage, lack of adequate physical activity, northeast region (relative to west region), no known chronic diseases, and dissatisfactory care. The top 5 most significant predictors of a lack of FBS test in those without diabetes were, in order, 1) no visits to the doctor in the past 12 months (aOR [95% CI]; 5.64 [5.34, 5.96]), 2) insurance status (no coverage vs. coverage; 1.62) [1.54, 1.69]), 3) age group (Ref: ≥65y; 18-35y: 2.45 [2.34, 2.56]; 35-50y: 1.46 [1.40, 1.52]; 50-65y: 1.04 [1.01, 1.08]), 4) BMI group (Ref: Low/Normal; Overweight: 0.79 [0.77, 0.82]; Obese: 0.62 [0.60, 0.64]), and 5) race/ethnicity (Ref: Non-Hispanic White; Non-Hispanic Black: 1.03 [0.98, 1.07], Asian Indian: 0.65 [0.58, 0.74]; Other Asian: 0.91 [0.83, 1.00]; Hispanic/Multiracial: 0.91 [0.86, 0.96]). The top predictors for those with diabetes were similar, although there were significantly greater odds of a lack of FBS testing in Non-Hispanic Blacks vs. Whites (1.24 [1.14, 1.35]).

**Conclusion:** More than half of the participants reported a lack of FBS testing in the past year; among those with diabetes, nearly 1 in 6 reported not having an annual FBS test. This reaffirms the need for long-term patient-physician relationships and aggressive follow-up in younger, male, uninsured, and/or lean individuals with or without diabetes.

# Diabetes Mellitus and Glucose Metabolism

#### **TYPE 2 DIABETES**

#### Racial/Ethnic Differences in Leisure-Time Physical Activity Among United States Adults With and Without Diabetes

Aayush Visaria, MPH, Nikhit Kethidi, BA, Rachana Chilakapati, BA, Jai Shahani, BA, Anurag Modak, BA, Megh Shah, BA. Rutgers New Jersey Medical School, Newark, NJ, USA.

**Background:** Physical activity (PA) is a key lifestyle recommendation for diabetes mellitus (DM) prevention and management. The purpose of this study was to describe the patterns of leisure-time, aerobic & muscle-strengthening PAs across races/ethnicities and DM status.

**Methods:** We included 91,386 adults  $\geq 18$  years from the 2011–2018 National Health Interview Surveys who were able to participate in light-moderate PA. Aerobic PA was classified per 2008 guidelines as inactive (0 minutes/week [min/wk] of moderate or vigorous activity), insufficiently active (0-150 moderate-equivalent min/wk, defined as sum of moderatelevel and 2\*vigorous-level PA), sufficiently active (150-300 moderate-equivalent min/wk), and highly active (>300 min/ wk of moderate-level PA, >150 min/wk of vigorous-level PA, or >300 moderate-equivalent min/wk). We also classified aerobic PA continuously in terms of metabolic equivalents (METs: 4 METs for moderate and 8 METs for vigorous PA). Musclestrengthening PA was dichotomized into ≥3 times/wk (adequate) and <3 times/wk (inadequate). Race/ethnicity was categorized as non-Hispanic White (NHW), non-Hispanic Black (NHB), Asian Indian (AI), Other Asian (OA), and Hispanic/ Other (H/O). We used self-reported DM-stratified multivariable logistic and linear regression to assess racial/ethnic differences in PA. All analyses accounted for the survey design and weights to obtain nationally representative estimates.

**Results:** Among the 91,386 participants, 45,676 (53%) were male, 11,835 (10%) were  $\geq 65$  years, and 5,106

(5.2%) had DM. Asian groups had lower adequate musclestrengthening PA than others (%[SE]: NHW, 35[0.3]%; NHB, 35[0.7]%; AI, 27[1.6]%; OA, 30[1.3]%; H/O, 34[0.8]%; p<0.0001). AIs also had a lower proportion of 'highly active' individuals (%[SE]: NHW, 67[0.2]%; NHB, 65[0.7]%; AI, 57[1.8]%; OA, 61[1.5]%; H/O, 67[0.8]%; p<0.0001). Non-DM AIs had mean (SE) 622 (133) lower METs than NHWs (covariate adjusted mean METs [SE]: NHW, 3,568 [305]; NHB, 3,873 [309]; AI, 2,946 [333]; OA, 3,107 [321]; H/O, 3,736 [325]; p<0.001). This difference was also present in those with DM (adjusted mean METs [SE]: NHW, 2,231 [314]; NHB, 2,231 [379]; AI, 1,366 [456]; OA, 1,847 [495]; H/O, 2,454 [401]; p=0.013). Non-DM AIs and OAs had ~30% lower odds of being at least 'sufficiently active' relative to NHWs (aOR [95% CI]: AI, 0.70 [0.56, 0.87]; OA, 0.72 [0.61, 0.85]). All races/ethnicities had lower odds of adequate muscle-strengthening PA compared to NHWs (aOR [95% CI]: NHB, 0.94 [0.90, 0.99]; AI, 0.68 [0.60, 0.79]; OA, 0.75 [0.68, 0.84]; H/O, 0.73 [0.69, 0.77]). These inverse associations persisted in DM-diagnosed OAs, but not AIs. Conclusion: Among those with and without DM, there exist racial/ethnic differences in strength-related and aerobic activities. Asian groups may benefit from aggressive counseling and PA interventions to both prevent and manage DM.

## Diabetes Mellitus and Glucose Metabolism TYPE 2 DIABETES

### Response to Twin Enabled Precision Treatment for Reversing Diabetes: An Initial Analysis at 4 Weeks of the Ongoing Randomised Controlled Trial

Paramesh Shamanna, MD<sup>1</sup>, Mala Dharmalingam, MD, DM<sup>2</sup>, Arun Vadavi, MD<sup>3</sup>, Jahangir Mohammed, MS<sup>4</sup>, Terrence Poon, MS<sup>4</sup>, Mohamed Thajudeen, MD<sup>1</sup>, Ashok Keshavamurthy, MD<sup>1</sup>, Suchitra Bhonsley, MBBS, Dip Diab<sup>1</sup>.

<sup>1</sup>Twin Health, Bangalore, India, <sup>2</sup>MS Ramaiah Medical College/ Hospital, Bangalore, Karnataka, India, <sup>3</sup>Sudha Prevention Center, Bangalore, India, <sup>4</sup>Twin Health, Mountain View, CA, USA.

**Introduction:** Technology enabled precision nutrition, a combination of macro, micro and biota nutrients, along with Continuous Glucose Monitoring (CGM) have been demonstrated to be a key for reversal of diabetes.

**Methods:** We conducted an initial analysis (n=23) of the ongoing randomized controlled trial of Twin Precision Treatment (TPT): a novel whole-body digital twin enabled precision treatment for reversing diabetes. The clinical and the biochemical parameters were evaluated as the longitudinal follow up at the first follow up visit at 4 weeks. The target sample size is 300 with an estimated duration of 5 years. Descriptive statistics were used

**Results:** 8/23 (35%) patients achieved the intended outcome of reversal of HbA1c and off any anti-diabetic medications. There was a statistically significant improvement in HbA1c % (8.5 ± 1.6 to 6.8 ± 0.66; p<0.0001), Fasting Blood Glucose mg/dL (FBS) (151 ± 44 to 98 ± 18; p<0.0001), HOMA2-IR (1.7 ± 0.64 to 1 ± 0.45; p=0.0001), HOMA2-Beta (53 ± 28 to 86 ± 38; p=0.0013), Systolic BP (129 ± 11 to 120 ± 11; p=0.008) and serum albumin g/dL (4.5 ± 0.21 to 4.2 ± 0.31;

J Endocrine Soc, Volume 5, Issue Supplement\_1, April-May 2021